Shanghai Junshi Biosciences Co Volatilidad
¿Qué es el Volatilidad de Shanghai Junshi Biosciences Co?
El Volatilidad de Shanghai Junshi Biosciences Co., Ltd. es 1.72%
¿Cuál es la definición de Volatilidad?
La volatilidad o el porcentaje promedio del rango verdadero (ATRP 14) es el ATR expresado como un porcentaje del precio de cierre.
Average true range percent (ATRP) measures volatility on a relative level. This is opposed to the ATR, which measures volatility on an absolute level. ATRP allows securities to be compared whereas ATR does not. That means lower-priced stocks won't necessarily have lower ATR values than higher-priced stocks.
The period used in the calculation is 14 days and the normalized indicator oscillates between 0 and 100 percent of recent price variation. Importantly, the indicator doesn't predict the direction of price but it describes the current volatility. The volatility is comparable across all securities and all markets.
Volatility expresses the degree of price movement. The use of ATRP as volatility compared to ATR is preferred in cases when different securities or different time periods are compared. Examples are stock screening, filtering strategies, and studying seasonality and volatility patterns over long periods of time and different markets
Volatilidad de compañías en Sector Health Care en OTC en comparadas con Shanghai Junshi Biosciences Co
¿Qué hace Shanghai Junshi Biosciences Co?
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
Empresas con volatilidad similar a Shanghai Junshi Biosciences Co
- Hamilton Enhanced U.S. Covered Call ETF tiene Volatilidad de 1.71%
- Urstadt Biddle Properties tiene Volatilidad de 1.71%
- Zagg Inc tiene Volatilidad de 1.71%
- Prudential Bancorp Inc tiene Volatilidad de 1.71%
- Biotest Ag Vz O.N. Z.Verk tiene Volatilidad de 1.71%
- AB Volvo (publ) tiene Volatilidad de 1.71%
- Shanghai Junshi Biosciences Co tiene Volatilidad de 1.72%
- American Water Works Co tiene Volatilidad de 1.73%
- Service International tiene Volatilidad de 1.73%
- Housing Development Finance tiene Volatilidad de 1.73%
- William Hill Plc tiene Volatilidad de 1.73%
- Unitedhealth Inc tiene Volatilidad de 1.73%
- First American Corp tiene Volatilidad de 1.73%